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We present a nanofluidic device for fluorescence-based detection and characterization of small lipid vesi-
cles on a single particle basis. The device works like a nano flow cytometer where individual vesicles are vi-
sualized by fluorescence microscopy while passing through parallel nanochannels in a pressure-driven
flow. An experiment requires less than 20 μl sample volume to quantify both the vesicle content and the
fluorescence signals emitted by individual vesicles. We show that the device can be used to accurately
count the number of fluorescent synthetic lipid vesicles down to a vesicle concentration of 170 fM. We also
show that the size-distribution of the vesicles can be resolved from their fluorescence intensity distribution
after calibration. We demonstrate the applicability of the assay in two different examples. In the first, we
use the nanofluidic device to determine the particle concentration in a sample containing cell-derived
extracellular vesicles labelled with a lipophilic dye. In the second, we demonstrate that dual-color detection
can be used to probe peptide binding to synthetic lipid vesicles; we identify a positive membrane-
curvature sensing behavior of an arginine enriched version of the Antennapedia homeodomain peptide
penetratin. Altogether, these results illustrate the potential of this nanofluidic-based methodology for char-
acterization and quantification of small biological vesicles and their interactors without ensemble averaging.
The device is therefore likely to find use as a quantitative analytical tool in a variety of fields ranging from
diagnostics to fundamental biology research. Moreover, our results have potential to facilitate further de-
velopment of automated lab-on-a-chip devices for vesicle analysis.
1. Introduction
Living organisms contain a multitude of phospholipid-based
vesicles with distinct biochemical, structural and physical
properties that allow them to fulfill well-defined biological
functions. Cell-secreted extracellular vesicles represent a cate-
gory of such vesicles and have attracted considerable atten-
tion recently for their emerging significance in intercellular
communication. In particular exosomes, extracellular vesicles
of endocytic origin,1,2 have been identified as key players for
example in the regulation of various biological processes.3–8 It
has also been suggested that extracellular vesicles, including
exosomes, are important in the pathobiology of cancer9,10 and
neurodegenerative diseases;10,11 these vesicles have therefore
been pointed out as promising diagnostic markers.12 Further-
more, artificial lipid vesicles, also called liposomes, are useful
membrane mimics for fundamental studies of biomolecular
interactions at the membrane interface13–17 or as drug deliv-
ery vehicles.18–20
In light of the high intrinsic prevalence and increasing sig-
nificance of phospholipid-based vesicles in biological systems
and of the pharmaceutical potential of liposome formula-
tions, there is an urgent need for development of new and ac-
curate methods capable of analyzing lipid-vesicle-containing
samples with respect to size, structure, composition and con-
tent. Characterization of small biological vesicles has, how-
ever, proven highly challenging, mainly due to their small
size (typically a few tens to a few hundreds of nanometers),21
but also due to the enormous degree of heterogeneity that is
characteristic for native vesicle samples.1,22–26 Body fluids,
for example, contain a broad variety of secreted vesicles
which differ in size, biomolecular finger prints and lipid con-
tents, reflecting the multitude of possible cellular origins and
biogenesis mechanisms.1,25 In view of this heterogeneity, it
has not only become increasingly essential to determine the
biomolecular identity of nanovesicles one by one, it has also
become important to accurately quantify vesicle numbers
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and to discriminate between vesicle fractions belonging to
different subpopulations. In the context of exosome research,
such analytic capability would, for example, make it possible
to identify and quantify vesicles carrying a specific disease
marker or to determine the tissue of origin of the different
vesicles found in samples collected from humans or model
organisms, allowing for better understanding of biological
functions and disease.
Electron microscopy (EM) has historically been a preferred
method to visualize single lipid vesicles, as it allows imaging
with nanometer resolution.27–29 Moreover, the possibility to
combine EM with immuno-gold staining has made it possi-
ble to detect specific molecules on the vesicle surface and
thereby to identify vesicle subpopulations.30,31 While this
technique can provide detailed information on vesicle mor-
phology and identity, its ability to accurately determine vesi-
cle size and subpopulation fractions is limited by low
throughput, artifacts due to sample preparation and limited
possibilities of multiplexing. The advent of techniques that
are capable of detecting fluorescence and scattering signals
from individual biological vesicles promises to increase
throughput in the characterization of vesicle size and num-
bers, but also to facilitate their multiplexed biochemical pro-
filing on a single vesicle level using fluorescent reporter
probes and immunostaining. In this context, nanoparticle
tracking analysis (NTA), which allows for the visualization of
the light scattered or fluorescence emitted by individual par-
ticles upon laser illumination,32 has gained in popularity over
the last years. With this method, vesicle numbers can be
quantified and the size distribution in samples can be esti-
mated upon tracking of their Brownian motion.24,33 Further-
more, fluorescence-based detection makes it possible to char-
acterize fluorescently labelled vesicle subpopulations.33
However, an accurate quantification of the intensity of the
emitted signal is challenging due to the three-dimensional
motion of the particle across the focal plane.34 Furthermore,
multiparametric detection of selected individual vesicles is
yet to be achieved with commercial instruments although
possible, in principle.
Multiparametric detection of the fluorescence and scatter-
ing signals generated from individual vesicles can be achieved
upon immobilization on a surface and using fluorescence
microscopy or label-free microscopy setups.35–38 Surface-
based fluorescence detection has been used, for example, to
probe protein binding to membranes,14 to investigate hetero-
geneities in vesicle lipid composition39 and to probe mem-
brane degradation on a single vesicle level.17,40 While
surface-based detection allows for a sensitive analysis of vesi-
cle populations,41 surface-immobilization has the drawback
of often requiring optimized surface chemistries and several
sample preparation steps which is time consuming and can
damage the sample. Furthermore, sample recovery for further
analysis, in particular in conjunction with sorting of vesicle
subpopulations, is cumbersome. An alternative and faster
method that overcomes the latter limitation is flow cytometry
which allows for solution-based high-throughput
multiparametric detection of particles. The method is
mostly used to analyse cells or microparticles but has also
been adapted for lipid vesicles.42 It is, however, only re-
cently that a high enough sensitivity could be achieved to
detect viruses or extracellular vesicles with diameters below
100 nm.43–46 Flow cytometry in combination with
fluorescence-activated sorting makes it possible to recover
subpopulations of analyzed particles.46 Conventional flow
cytometers however operate with quite large sample vol-
umes47 which has prompted the development of chip-based
flow cytometers47–50 where the scaling down of the dimen-
sions of the channels to a few hundred nanometers makes
it possible to analyze sub-micrometer vesicles,51 viruses52 or
even individual biomolecules.53
In this study, we implement and validate a nanofluidic de-
vice for single vesicle analysis of biological samples that func-
tions as a miniturized nano flow cytometer. The device con-
sists of hundreds of parallel nanochannels in which lipid
vesicles can be introduced under a steady flow by means of
pressure. The device, which has previously mostly been used
in a stationary mode to study DNA and DNA–protein com-
plexes,54,55 can be imaged under a standard epi-fluorescence
microscope, offering cheap and easily implemented means of
measurement and detection. Our nanofluidic-based assay al-
lows solution-based quantification of the fluorescence signal
of individual vesicles with sizes in the 100 nm range and for
quantification of their concentration down to femtomolars.
Two potential applications are presented; in the first we
quantify the concentration of extracellular vesicles isolated
from cell culture media and in the second we show that a
short drug delivery peptide with cell-penetrating properties
binds to a membrane with a hitherto unreported curvature-
dependent affinity. Taken together, our device is fast, easy to
operate, compatible with standard epi-configuration micros-
copy and requires very low amounts of starting material; this
makes it a promising tool in the study of extracellular vesicle
subpopulations and other types of heterogeneous artificial or
biological nanoparticles.
2. Experimental
2.1. Nanofluidic device fabrication
The design of the nanofluidic device is shown in Fig. 1. In
brief, it consists of a series of 250 parallel nanochannel with
a period of 2 μm. Each individual channel has a square pro-
file with 300 nm sides. The nanochannels are connected by
two microchannels facilitating device loading. The nano-
fluidic devices were fabricated using standard micro- and
nanofabrication techniques as described in detail elsewhere.55
In brief, the fabrication comprised five processing steps
based on optical lithography (OL, system MA 6/Suss Micro-
Tec), electron beam lithography (EBL, system JBX-9300FS/
JEOL Ltd), reactive ion etching (RIE, system Plasmalab 100
ICP180/Oxford Plasma Technology), deep reactive ion etching
(DRIE, system STS ICP/STS), fusion bonding (system AWF 12/
65/Lenton) and dicing (system DAD3350/Disco). Alignment
Lab on a Chip Paper
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
832 | Lab Chip, 2017, 17, 830–841 This journal is © The Royal Society of Chemistry 2017
marks for both OL and EBL were etched into the surface of a
p-type 4″-Si wafer with 2 μm thermal oxide using OL and
fluorine based RIE. Subsequently, arrays of nanochannels
were defined in a resist layer with EBL and transferred into
the thermal oxide with fluorine based RIE. After that, micro-
fluidic structures connecting to the nanochannels were fabri-
cated with OL and fluorine based RIE, before using OL and
DRIE to etch holes through the substrates, serving as inlets
and reservoirs. The substrate was then fusion bonded to a
200 μm thick 4″-pyrex wafer in Ar atmosphere for 5 h at 550
°C and diced into individual chips.
2.2. Lipid vesicle preparation
The lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-
dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DOPG), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino-
Ĳpolyethylene glycol)-2000] (ammonium salt) (DSPE-PEG2000)
and the fluorescently labelled lipid 1-palmitoyl-2-{6-[(7-nitro-
2-1,3-benzoxadiazol-4-yl)amino]hexanoyl}-sn-glycero-3-phospho-
choline (NBD-PC) were purchased from Avanti Polar Lipids
Inc. (Alabaster, USA). Fluorescently labelled ATTO 550-DOPE
was purchased from Atto-Tec GmbH (Siegen, Germany). Fluo-
rescent vesicles for channel passivation were made of POPC
containing 1 wt% NBD-PC. Vesicles for the peptide binding
assay were prepared from a mixture of DOPC/DOPG/DSPE-
PEG2000/ATTO 550-DOPE at a molar ratio of 60 : 37 : 2.5 : 0.5
where DSPE-PEG2000 lipids were included to avoid peptide-
induced lipid vesicle aggregation.56 All other vesicles were
prepared from POPC doped with small amounts of ATTO 550
(between 0.02 mol% and 2.2 mol%). All vesicles were pre-
pared by the lipid film hydration and extrusion method.57 In
brief, lipids dissolved in chloroform were mixed in a round
bottom flask followed by solvent evaporation under a gentle
nitrogen stream whilst constantly rotating the flask. The
dried film was then left in high vacuum for at least 2 h to re-
move any residual solvent. The resulting dry lipid film was
hydrated using the indicated buffer solution and extruded
11× in an Avanti Mini Extruder (Avanti Polar Lipids Inc., Ala-
baster, USA) at a pressure of 10 psi. Vesicles for channel pas-
sivation58 were extruded through a 30 nm pore membrane.
All other vesicles were prepared using a 100 nm pore mem-
brane and yielded vesicle populations with a mean diameter
of around 150 nm. In all cases, except for the vesicles used in
the peptide binding assay, the dry lipid film was hydrated in
phosphate buffered saline (PBS; 0.01 M phosphate, 0.0027 M
potassium chloride and 0.137 M sodium chloride, PH 7.4,
Sigma Aldrich, Stockholm, Sweden). The vesicles used in the
peptide binding assay were produced in 10 mM HEPES, 5
mM NaOH, 1 mM EDTA, 0.1 M NaCl, pH 7.4.
The theoretical average number of lipids (N) per vesicle
was calculated from simple geometrical considerations as-
suming that the vesicles were monodisperse and unilamellar.
The mode diameter, i.e. the value that appears most often in
the distribution, measured by nanoparticle tracking analysis
(NTA), was used as an average vesicle size (d). An average
lipid surface area (A) of 0.65 nm2 (ref. 59) was assumed for
all lipids regardless of whether they were in the inner or outer
leaflet. The number of lipids was therefore estimated as:
2.3. Nanofluidic device measurements
Prior to each measurement, the surface of the nanochannels
in the fluidic device was passivated against non-specific vesi-
cle and peptide binding by introducing a POPC supported
lipid bilayer formed by surface-induced vesicle rupture.58
This passivation was achieved by loading 20 μl of a vesicle
suspension (0.5 mg ml−1 lipids) into inlet 1. The vesicle solu-
tion was then flushed to the inlets of the nanochannels by
applying pressure to inlet 1 and subsequently into the nano-
channels by applying a pressure of 0.5 bar to inlets 1 and 2
(see Fig. 1a) for at least 30 min. In all experiments, except for
those performed with carboxyfluorescein-labelled peptides,
successful formation of a supported lipid bilayer in the
Fig. 1 Nanofluidic device. (a) Schematic representation of the nanofluidic device consisting of parallel nanochannels with a square profile of 300
nm connected by two microchannels. The microchannels are used for sample injection; the vesicles are observed by recording time lapse movies
while the sample is passing through the nanochannels. (b) Snap shot (single image frame) of individual vesicles containing 0.6 mol% ATTO 550
imaged in the nanofluidic device using an epi-fluorescence microscope. Scale bar: 50 μm. (c) Detected movement of individual vesicles in the
nanofluidic channels. For vesicle quantification, the vesicles were counted when passing the gate displayed as a red rectangle.
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channel was visually verified by fluorescence microscopy
using vesicle containing 1 wt% NBD-PC. In the experiments
with carboxyfluorescein-labelled peptides, non-fluorescent
POPC vesicles were used for channel passivation. Uniform
light intensities along typically >95% of the nanochannels
for a successful experiment, indicated even spreading of the
passivating bilayer and that the majority of channels were
open (ESI† S1).
After passivation, the bilayer was rinsed with buffer
followed by deposition of a 20 μl sample droplet in inlet 1 of
the nanofluidic device. Pressure was applied to drive the sam-
ple into the microchannel; followed by subsequent and uni-
form application of pressure on inlet 1 and 2 which drives
the sample into the nanochannels. If not stated otherwise,
the applied pressure across the nanochannels was 25 mbar
and the total recording time was 2 minutes.
2.4. Fluorescence microscopy
All nanofluidic device measurements were carried out with
the device mounted in a custom made sample holder that in
turn was mounted on a Nikon Eclipse Ti-E inverted micro-
scope using a 60× magnification (NA = 1.49) oil immersion
objective (Nikon Corporation, Tokyo, Japan). The microscope
was equipped with a mercury lamp (Intensilight C-HGFIE;
Nikon Corporation) for excitation, a TRITC and FITC filter
cube (Nikon Corporation) and an Andor iXon+ EMCCD cam-
era (Andor Technology Ltd, Belfast, Northern Ireland) for de-
tection. A beam splitter (Optosplit II, Andor technology Ltd)
equipped with a dual bandpass filter (bandpass centers at
468/533 nm), a dual bandpass dichroic mirror (bandpass cen-
ters at 493/574 nm), a dichroic mirror (cutoff at 562 nm) and
two emission filters (green: 514/30 nm; red: 617/73 nm) was
used for simultaneous two-channel fluorescence detection.
2.5. Vesicle tracking
The collected image series (time-lapse movies) were
processed and analyzed with MatLab (MathWorks, Inc., Na-
tick, USA) using in-house scripts. Vesicles were detected
using an intensity threshold chosen individually for each
time-lapse movie. The fluorescence cutoff threshold was cho-
sen after visual inspection in order to detect a maximum
number of vesicles while excluding the background noise.
Single particle tracking was implemented using local nearest-
neighbor linking60 and events whose displacements were be-
low a set maximal distance were connected across frames.
The maximal distance was determined for each time-lapse
movie individually; the parameters were refined by visual in-
spection of the tracking result. Additionally, the maximum
allowed movement angle was set to a fixed value of 15° to
avoid artifactual crossing of the track into neighboring chan-
nels. An extrapolating tracking function was further used to
facilitate the tracking of vesicles which due to their low
signal-to-noise ratio were found to disappear and reappear in
consecutive frames. Specifically, a vesicle was only taken into
account if it could be tracked for at least 4 consecutive
frames. If a vesicle disappeared, a theoretical event was placed
at the expected extrapolated position. A maximum of 4 extrap-
olated positions was tolerated before the vesicle was consid-
ered lost. These additions to the particle tracking algorithm,
unique for vesicles flowing in a one-dimensional channel, sig-
nificantly improved the quality of the tracking algorithm as
further illustrated in the ESI† (S2). All parameters (i.e. maxi-
mum allowed travel distance, minimum allowed distance be-
tween two vesicles and set background level) were optimized
by visual inspection of the tracking result. For each frame,
each detected vesicle was located with sub-pixel accuracy by
applying a Gaussian fit to its intensity distribution.
For two-color fluorescence detection, the images corre-
sponding to the individual fluorescence channel on the
microscope were first evaluated individually as described
above. The images for both channels were then cropped to
the same dimension and accurately overlaid using the convo-
lution theorem of the Fourier transform61 yielding the rela-
tive displacement of the movies in the individual fluores-
cence channels and allowing for a connection between them.
2.6. Vesicle quantification
The vesicle concentration in a sample was determined by
counting the number of vesicles passing through the nano-
channels of the device during the time period of the experi-
ment. The total sample volume (analysed within the time pe-
riod) was determined from the sample flow rate, the
nanochannel area, the number of channels in the image and
the experiment time. For vesicle counting, a detection rectan-
gle was defined with a width set to the maximum travel dis-
tance (section 2.3). To minimize artifacts due to possible
bleaching, the rectangle was placed where the vesicles enter
the nanochannels (see Fig. 1c). The sample flow rate was esti-
mated as the average mean displacement of all vesicles in the
measurement. It was therefore assumed that the recorded
vesicle speed reflects the fluid velocity and therefore that the
friction acting on the vesicles is negligible both for large and
small vesicles. This assumption is supported by the observa-
tion that the vesicle speed is independent of the vesicle inten-
sity, which relates to its size (see ESI† S3). The number of
open channels in the field of view was obtained from
recorded images that showed all detected tracks. Some chan-
nels (typically <5%) were clogged, most likely due to defects
during fabrication or unsuccessful passivation, and were ex-
cluded from the analysis. To ensure good statistics, we made
sure that at least 300 events were recorded in the field of view
(containing ∼100 nanochannels), leading to a 95% probabil-
ity that a vesicle has passed through an open channel. In this
case, the underestimation of the number of open channels is
therefore below 5%. To gain a rough estimate of the number
of vesicles found in the microchannels (control experiment
shown in ESI† S4), the number of vesicles detectable on at
least 5 individual images were counted. The total volume was
taken as the area of an image multiplied by the thickness of
the microchannel (1 μm). The thickness was smaller than the
imaging depth.
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2.7. Vesicle fluorescence intensity analysis
In order to determine the fluorescence intensity of individual
vesicles flowing through the nanochannels of the device, the
pressure was set to the minimum value that allows for a regu-
lar unidirectional flow. This resulted in flow speeds of ap-
proximately 20 μm s−1. This was done to avoid artifacts due
to signal smearing at high flow rates and thereby ensure max-
imal sensitivity.
The total intensity of an event (defined as one vesicle in
one image) was calculated by summing up all pixel values in-
side a square around the detected position of the event. The
size of this square was approximately (value rounded to inte-
ger values) three times the standard deviation of a Gaussian
fit to its intensity on a given image. For the vesicles labelled
with ATTO 550, the intensity was found by averaging the
intensities of all events on the track since for those vesicles
bleaching did not significantly affect the measurement. For
the dual channel measurements where we detected emission
from carboxyfluorescein, which is a comparatively weak emit-
ter and sensitive to photo-bleaching, the intensity was deter-
mined by fitting a straight line to all recorded events and
evaluating it at the first detected location of the vesicle, to
minimize the effect of bleaching.
The recorded intensity distributions of vesicle samples
were plotted as vesicle fraction versus square root of the mea-
sured intensity and fitted with a log-normal function. For less
intense vesicle samples, fluorescence data fitting became dif-
ficult due to the absence of data points in the low intensity
range. To improve the accuracy of the fit, a truncated fit with
a cutoff at the vesicle with the lowest intensity was used. This
truncated fit neglects the non-detectable fraction in the ex-
perimental data below the cutoff and thereby allows for an
improved determination of the mode value as visualized in
ESI† S5. The squared mode value of the fit, herein referred to
as mode intensity, was used as a single measure of the over-
all ensemble-averaged sample intensity.
2.8. Extracellular vesicle experiments
Extracellular vesicles floating at a buoyant density between
1.24 g mL−1 and 1.31 g mL−1 were extracted from the condi-
tioned media of a human mast cell line (HMC-1.2) following
the protocol previously published by Lässer et al.62 The total
protein content of the vesicle stock was determined to be
0.52 mg ml−1 using the Pierce bicinchoninic acid (BCA) pro-
tein assay kit (ThermoFisher Scientific, Gothenburg, Sweden)
according to the manufacturer's instructions. Prior to each
measurement, the vesicles were fluorescently labelled with
the fluorescent cell linker PKH26 kit (Sigma-Aldrich, Stock-
holm, Sweden), in which the lipophilic PKH26 dye labels
lipid membranes by intercalation into the bilayer.63 In brief,
the dye stock (100 μM, ethanol) was diluted 50× in the dilu-
ent C solution accompanying the kit. The vesicles were di-
luted 12.5× in the same solution yielding a final extracellular
vesicle concentration of 42 μg ml−1. The two solutions were
subsequently mixed at equal volumes and incubated for
5 min at 6 °C. Dye and diluent C were then separated from
the labelled extracellular vesicles using MicroSpin S-200 HR
size exclusion columns (GE Healthcare Life Sciences, Upp-
sala, Sweden) centrifuged at 700 × g for 2 minutes. The run-
ning buffer contained 10 mM TRIS-HCl, 1 mM EDTA, (pH
7.4). Without taking eventual material loss in the filters into
account, the final exosome suspension after dilution
contained 21 μg ml−1 extracellular vesicles (total protein con-
tent). The extracellular vesicles were thereafter loaded into
the nanofluidic device and analyzed for 10 minutes.
2.9. Peptide binding experiments
The DOPC/DOPG/DSPE-PEG2000/ATTO 550-DOPE vesicle
stock solution was diluted to 50 μg ml−1 (total lipid content)
and then mixed with a carboxyfluorescein-labeled arginine-
enriched variant of the Antennapedia homeodomain peptide
penetratin denoted PenArg64 in which all lysines have been
substituted for arginines.65,66 The peptide was prepared by
solid phase synthesis (80% purity) by Innovagen AB (Lund,
Sweden). The samples were incubated under constant shak-
ing for at least one hour at room temperature and thereafter
loaded into the nanofluidic device for analysis. 10 mM
HEPES, 5 mM NaOH, 1 mM EDTA, 100 mM (pH 7.4) was
used as peptide binding buffer.
2.10. Nanoparticle tracking analysis
Vesicle size distributions were obtained using a NanoSight
LM10 (Malvern Instruments Ltd, Malvern, UK) equipped with
a 640 nm laser. For each sample, 5 measurements were
performed and averaged. NTA data using both light scatter-
ing and fluorescence were obtained using a NanoSight LM10
equipped with a 532 nm laser and a 565 nm emission filter.
The movies were analyzed with the software NTA 2:2
(Malvern Instruments Ltd, Malvern, UK).
2.11. Fluorimeter measurements
The average (bulk) fluorescence intensities of suspensions
containing vesicles labelled with ATTO 550 lipids were
obtained using a QM-4/2005 spectrofluorimeter (Photon
Technology International Inc., North Edison, USA). The sam-
ple was excited at a wavelength of 550 nm and emission spec-
tra were recorded between 570 nm and 720 nm. The emission
value at the peak was used as a representative value of the
fluorescence intensity.
3. Results and discussion
3.1. Nanofluidic device
In this work, nanofluidic devices fabricated in a silicon wafer
were used as nano flow cytometers to detect individual
flowing fluorescently labeled lipid vesicles, ∼100 nm in diam-
eter, as they passed through a detection volume. The fluores-
cence signal was detected using standard epi-fluorescence
microscopy (Fig. 1, ESI† Movie M1). As illustrated in Fig. 1a,
the device consisted of a series of parallel nanochannels (250
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channels with a period of 2 μm) connected by two micro-
channels. The microchannels were used for fast and efficient
loading of the device while the nanochannels were used for
vesicle observation. The nanochannels in the device used in
this study had a square profile with 300 nm sides, but the di-
mensions can be tuned to suit the application of interest.
Channels with restricted diffusion in the direction perpendic-
ular to the imaging plane, i.e. “one-dimensional” nano-
channels (allowing free movement only in one dimension) or
“two-dimensional” nanoslits (allowing free movement in two
dimensions) offer the advantage over deeper channels that
they keep the vesicles in focus throughout the experiment.
This makes it possible to accurately quantify the fluorescence
intensity even of weakly fluorescent objects without surface
immobilization and with a standard epi-fluorescence micro-
scope. An advantage of one-dimensional nanochannels over
two-dimensional nanoslits is that they ensure that the vesi-
cles are well-separated, facilitating the unique detection of in-
dividual vesicles by the tracking software. Indeed, track cross-
ing, which causes major problems during single particle
tracking, can be excluded, making it possible to perform exper-
iments at high vesicle concentrations. A further advantage of
one-dimensional nanochannels is that the trajectory is fully
predictable even at lower flow rates, which increases the speed
of the data analysis significantly. Trajectory prediction in-
creases sensitivity because it facilitates the detection of vesicles
with intensities close to the background intensity, or of labels
whose intensity may fluctuate (e.g. quantum dots), even if they
are lost for a few frames. Trajectory prediction also makes it
possible to discriminate the signal from the background noise
which is random and therefore non-unidirectional and to
colocalize two or more colors in a straight forward fashion.
The use of a miniaturized device, such as the one
presented here, offers the possibility of analyzing vesicle-
containing samples with very low sample consumption. For
convenience, 20 μl of sample was loaded in a typical experi-
ment, although this could be scaled down to a few microli-
ters in the current device, or even less if the design of the in-
let is adjusted. During the experiment, the amount of sample
actually analyzed was typically in the nanoliter range. With-
out pushing the limits of our assays (see section 3.2), sam-
ples containing ∼109 vesicles per ml (low picomolar regime),
i.e. concentrations of relevance in the context of cell-secreted
vesicles,26 could be studied without pre-concentrating the
sample. This is a major advantage and illustrates how our
method is well-suited for analysis of rare and precious biolog-
ical samples.
3.2. Vesicle quantification
A first key aspect in the context of characterizing vesicle sam-
ples is the possibility to accurately quantify vesicle num-
bers.26 This is, for example, essential for the development of
extracellular-vesicle-based diagnostics where extracellular
vesicle secretion profiles of healthy and diseased individuals
are compared. Absolute quantification is also important for
accurate determinations of the potency of vesicles with re-
spect to their ability to induce a biological response in a re-
cipient cell; this is for example relevant in the context of
liposome-based drug delivery or for understanding exosome-
mediated intercellular communication.
To demonstrate the potential of our nanofluidic-based
tool to quantify the number of vesicles present in a sample,
proof-of-principle experiments were performed using a dilu-
tion series of a sample containing fluorescently labeled lipid
vesicles doped with 0.6 mol% ATT550-DOPE. At this dye
concentration, the average-sized vesicles in our samples
contained approximately 1000 fluorophores and the smallest
approximatively 400 fluorophores, making them clearly visi-
ble. As seen in Fig. 2a, a linear dependence between the
detected number of vesicles and the lipid concentration was
observed for a lipid concentration range spanning over 3
orders of magnitude (from 130 nM to 254 μM of starting lipid
material). This result indicates that the measurement perfor-
mance was independent of the actual sample concentration,
at least in the tested range. The corresponding concentration
of vesicles detected in our experiment ranged from 170 fM to
500 pM (Fig. 2a). The limiting factor for low concentrations
Fig. 2 Vesicle quantification. (a) Measured vesicle concentration
(vesicles containing 0.6 mol% of ATTO 550-DOPE) as a function of the
amount of lipids used to prepare the films, for a dilution series of the
same sample. (b) Measured vesicle concentration for a sample
containing 1 μg ml−1 lipid. The vesicle concentration was either
estimated from geometrical considerations (numerical) or measured
using the nanofluidic-based assay or fluorescence-based nanoparticle
tracking analysis (NTA). Measured values are the average and standard
deviations of at least 3 measurements.
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is the time required to collect enough data points. While a
concentration determination at 500 pM could be carried out
within 2 minutes, yielding as many as 5000 events, the con-
centration determination of the 170 fM sample required a
runtime of 2 hours to ensure good statistics (i.e. a couple of
100 detected events). A major limitation at high concentra-
tions is that the channels become too crowded to accurately
resolve individual vesicles. This can be overcome by diluting
the sample before loading into the device, extending the dy-
namic range dramatically. The absolute vesicle concentration
of the samples measured in the nanofluidic device were
found to be in excellent agreement with concentrations esti-
mated from fluorescence-based NTA experiments carried out
with Malvern's NanoSight, a commercial instrument com-
monly used for vesicle quantification (Fig. 2b).24,32 As shown
in Fig. 2b the measured concentrations were also in good
agreement with theoretical calculated values (yielding the ab-
solute maximum of vesicles without considering lipid losses
during preparation), estimated from the total amount of lipids
weighed in at the start of the vesicle preparation, the volume
and geometrical considerations based on a monodisperse vesi-
cle sample (see section 2.2 for details). This indicates that our
nanofluidic device functions at least as well as a commercial
instrument with respect to counting the number of fluorescent
vesicles present in solution and that the number of detected
vesicles is realistic. A control experiment comparing the num-
ber of vesicles present in the micro- and nanochannels showed
that the difference in the number of vesicles detected in the
both channel types was <10% (see ESI† S4), confirming that
there is no discrimination in our device at the step where the
vesicles enter into the nanochannels.
3.3. Intensity measurements and size determination
An essential aspect of the characterization of heterogeneous
samples is the possibility to detect and quantify the fluores-
cence emitted by individual vesicles. This makes it possible,
for example, to investigate membrane-mediated biomolecular
recognition processes on a single vesicle, to characterize bio-
molecular heterogeneity of individual vesicles via immuno-
staining, and to identify vesicle subpopulations.
The second part of this work was therefore devoted to
accurately quantifying the fluorescence intensity emitted by
single lipid vesicles. A representative intensity distribution
obtained with vesicles containing 0.6 mol% ATTO 550-DOPE
(i.e. ∼1000 fluorophores per vesicle if the size is assumed to
be 150 nm (Fig. 3a)) can be seen in Fig. 3b. Under the
assumption that the fluorophores are equally distributed
among vesicles of different size, the square root of the
intensity is expected to be proportional to the diameter of the
vesicles and the data can therefore be fitted with a log-
normal distribution67 (solid line in Fig. 3b). Importantly, no
cutoffs in the data were observed in either the high or low
intensity value ranges. This indicates that the whole vesicle
population entered the channels and that not even the
largest vesicles present in the samples were restricted. Fur-
thermore, it indicates that all vesicles present in the sample,
even the smallest and thus least intense ones, were confi-
dently detected. On the other hand, for vesicles prepared with
a lower fraction of fluorophores, a cutoff in the low intensity
Fig. 3 Size and intensity distribution of vesicles labeled with a
fluorescent lipid. (a) Size distribution of the vesicles as measured with
nanoparticle tracking analysis, NTA (mean (solid line) ± standard
deviation (dotted lines)). The mode of the distribution is at 152 nm. (b)
Square root of the intensity (lower y axis) versus vesicle fraction for
vesicles containing 0.6 mol% ATTO 550 (exposure time: 5 ms). The
distribution can be fitted with a log-normal function. Calibration of the
mode value against the NTA measurement shown in (a) yields the di-
ameter value in nanometer (upper y axis). (c) Square root of the inten-
sity versus vesicle fraction for vesicles containing 0.02 mol% ATTO 550
(exposure time 50 ms).
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range was observed (Fig. 3c). To ensure maximal accuracy in
the determination of the mode value also for these distribu-
tions, a truncated fit with a cutoff at the vesicle with the low-
est intensity was applied (see materials and methods section
2.7 and ESI† S5).
It is possible to obtain the size of the vesicles analysed in
our device under the assumption that the fluorescent lipids
are equally distributed among vesicles of different sizes and
hence that the fluorescence intensity is directly proportional
to the vesicle's surface area. To achieve this, we calibrated
our data by nanoparticle tracking analysis (NTA), but other
calibration methods that provide absolute size determina-
tion, such as for example dynamic light scattering (DLS),
should also be suitable. Upon calibration, it was possible to
compare the mode value of the log-normal fit to our data and
the maximum of the size distribution measured by NTA,
using the same sample. This allowed us to directly determine
the vesicle size from the corresponding fluorescence intensity
(Fig. 3b). Altogether, size determination makes it possible to
relate biomolecular recognition with the vesicle size, for ex-
ample, in the context of studying curvature-sensing
proteins.68
The ability to accurately determine intensity distributions
and the measurement reproducibility was further investi-
gated using vesicles that contained between 0.02 mol% and
2.4 mol% ATTO 550, i.e. on average between 40 and 4000
fluorophores per vesicle. As further detailed in materials and
methods (section 2.7), the mode of the intensity distribution
was used as a representative of the overall sample intensity
measured with the nanofluidic device.
This value was compared to the average fluorescence
intensity of the vesicle sample measured with a fluorimeter.
As shown in Fig. 4a, the signal obtained from our
nanofluidic-based assay scales linearly with the intensity de-
termined by fluorimetry for fluorophore concentrations be-
tween 0.2 mol% and 2.4 mol%. At lower fluorophore concen-
trations, the average signal is overestimated, leading to a
deviation from the linear behavior (see Fig. 4a and ESI† S6).
Indeed, inaccuracies in the log-normal fit, due to an in-
creased presence of non-detectable vesicles, lead to a shift in
the peak of the log-normal distribution towards higher mode
intensity values (see Fig. 4a).
To gain further insights into the percentage of vesicles de-
tectable for different concentrations of ATTO 550-DOPE, we
quantified the number of vesicles counted for vesicles
containing different amounts of fluorophores. As shown in
Fig. 4b, the number of detected vesicles plateaued at ATTO
550-DOPE concentrations above 0.4 mol%, reaching 100%,
indicating that most vesicles are detected at the highest
fluorophore concentrations. The percentage of vesicles de-
tectable as function of the vesicle's ATTO 550-DOPE content
estimated from the nanofluidic-based assay was compared to
the one obtained with the commercial fluorescence-based
NTA. Both techniques had comparable sensitivities (Fig. 4b)
and the current limit of detection with our experimental
setup and choice of dyes lies at ∼100 fluorophores per vesi-
cle. This was estimated from the percentage of vesicles de-
tectable and the known size distribution, making it possible
to estimate the smallest lipid vesicle detectable and its
fluorophore content. However, it should be stressed that the
number of fluorophores detectable mainly depends on the
quality of the dye and on the experimental setup (micro-
scope, camera). Indeed using bright dyes and appropriate in-
strumentation, sensitivities down to the single fluorophore
level have been reached in nanofluidic channels.69
3.4. Detection and quantification of extracellular vesicles
To demonstrate the applicability to study biological samples,
we used the nanofluidic-based assay for extracellular vesicle
concentration quantification. Extracellular vesicles were
obtained from the supernatant of a human mast cell line and
labelled using the self-inserting membrane dye PKH26 (see
Fig. 4 Influence of the fluorophore content on the vesicle intensity.
(a) Vesicle mode intensity values as determined with the nanofluidic-
based assay using 5 ms exposure times versus average fluorescence
intensity as measured by fluorimetry. The average and standard devia-
tion for at least 3 independent measurements is reported. The corre-
sponding mol% of ATTO 550-lipids in the vesicles is indicated in the
graph. Gray solid line: linear fit (0.07% point is excluded from the fit).
(b) Average number of vesicles detected for measurements using the
nanofluidic-based assay (black squares) and by fluorescence-based
NTA (grey dots). The left y-axis is the data normalized using the num-
ber of vesicles detected at 0.6 mol% ATTO 550-DOPE (nanofluidic-
based assay) as a reference (100%). The right y-axis is the absolute
concentration measured. Nanofluidic-based assay data: average and
standard deviation of 3 independent measurements.
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materials and methods section 2.8). The vesicles were success-
fully visualized (Fig. 5a), and flowed through the nanochannels
without hinderance; >95% of the channels were found to be
open (Fig. 5b). This indicates that the lipid passivation of the
nanochannels is suitable also for biological samples. The la-
belled extracellular vesicles exhibited rather weak intensities
(compared to background) but due to the steady flow and uni-
directional motion of the vesicles in the nanofluidic device it
was possible to accurately predict their movement and thus de-
tection was possible. The extracellular vesicle concentration of
our stock sample of 0.52 mg ml−1 (total protein content) was
estimated to be 80 pM. This is in the same order of magnitude
as that estimated in a fluorescence-based NTA measurement
of an equally prepared extracellular vesicle sample while the
protein-to-particle number ratio is on the same order of mag-
nitude as the one reported in other studies.70 Furthermore, as-
suming a buoyant density of 1.28 g ml−1 and an average vesicle
diameter of 150 nm, it can be estimated that the proteins con-
tribute to about 20% of the vesicle's buoyant mass.
3.5. Two-colour recording of peptide binding to vesicles
Microscopy-based imaging of vesicles in the nanochannel de-
vice allows for simultaneous recording of at least two emis-
sion colors, which makes it possible to carry out co-
localization experiments. Using the nanofluidic-based assay,
we demonstrate that co-localization of two emission colors
and ratiometric intensity measurements can be used to ana-
lyze the binding of a peptide to the lipid vesicle membrane.
As model we used an arginine-enriched variant of the
Antennapedia homeodomain peptide penetratin (PenArg).66
This cationic cell-penetrating peptide exhibits superior up-
take characteristics compared to wild type penetratin.71 It
adopts an amphipathic α-helical configuration upon interac-
tion with negatively charged lipid vesicle membranes and
binds in the interface region, parallel to the membrane sur-
face.72 We used a PenArg variant labelled with carboxy-
fluorescein (CF) at the N-terminus to investigate its binding
to negatively charged vesicles containing 37 mol% DOPG
lipids and 0.5 mol% ATTO 550-DOPE. The peptide concentra-
tions ranged between 5 μM and 20 μM. The possibility of
predicting the position of the vesicle from the relatively
bright red lipid signal and then measuring the fluorescence
intensity at the determined position for the much weaker
green peptide signal significantly improved the detection of
the peptide signal.
Since the data collected gives information on the size-
distribution of the vesicles via analysis of the red lipid sig-
nal, we could directly analyze our data for curvature-related
effects. This was done by considering the dependence of
the ratio of the green and the red signal, which reflects the
peptide density at the membrane surface, on vesicle size
(absolute intensity of the red signal). As shown in Fig. 6a,
the PenArg peptide displays an increased affinity for
smaller vesicles, i.e. for larger positive membrane curvature.
This was observed at all peptide concentrations as further
illustrated in Fig. 6b. Furthermore, in all cases, the peptide
surface-density increased with increased peptide concentra-
tion in bulk for concentrations up to 20 μM, indicating
that at those concentrations the peptide does not saturate
the membrane surface. At peptide concentrations higher than
20 μM, the incubated vesicles started to aggregate, as also
reported by others,73 and resulted in clogging of the channels.
Curvature dependence, in particular increased affinity for
small vesicles, has been demonstrated for several peptides
and also other molecules binding to lipid mem-
branes,14,68,74,75 but has not been discussed before in the
context of penetratin and its variants. Positive-curvature sens-
ing has mainly been associated with the increased amount of
defects, e.g. hydrophobic pockets, exposed upon membrane
bending into small vesicles.76 These defects can increase
binding of certain types of proteins by facilitating the inser-
tion of hydrophobic residues.77 It is likely that a similar
mechanism is responsible for positive-curvature sensing in
the case of PenArg, in particular since this peptide is known
to bind lipid vesicles as an amphipathic helix.72 Taken to-
gether, these results illustrate the potential of the
nanofluidic-based assay in the context of probing biomolecu-
lar interactions occurring at membrane surfaces. A major ad-
vantage over other techniques, including surface-based ones,
Fig. 5 Extracellular vesicle visualization. (a) Visualization of individual
extracellular vesicles labelled with PKH26 in the nanofluidic channel.
The red circles mark the position of the vesicles. (b) Plot of the
detected tracks showing no sticking events and 99 open channels (i.e.
<5% of the channels are empty), thereby indicating than most
channels in the device are open during the experiment.
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is that sampling is carried out within a couple of minutes
since no surface anchoring procedure is required.
4. Conclusion
We have presented a number of experiments based on a
nanofluidic device setup functioning as a nano flow
cytometer. This new methodology allows for quantification
and characterization of fluorescent vesicles in solution and
for simultaneous multi-channel quantification of fluores-
cence intensities. The device exhibits low sample consump-
tion, is easy to operate and is compatible with standard epi-
fluorescence microscopy. The device allows for single vesicle
analysis and particle concentration determination with an ac-
curacy and sensitivity equaling that of standard NTA, however
with the advantage of allowing multi-color detection. We
demonstrate that the device can be used to count single vesi-
cles in biological samples, such as exosomes, and to detect
binding reactions occurring at the surface of individual vesi-
cles. This paves the way to a number of exciting applications
in biological and medical sciences. In the context of the study
of extracellular vesicles, it will, for example, offer the possibil-
ity to investigate vesicle subpopulations characterized by the
presence of specific biomolecules on the surfaces, providing
understanding of their role in intercellular communication
in health and disease. The assay is also likely to find applica-
tions in the study of liposomes, in the context of the develop-
ment of drug delivery vehicles as well as for fundamental
studies of membrane proteins and bilayer-mediated binding
reactions. Furthermore, the possibility of quantifying the
number of particles found in solution makes our tool well-
suited for diagnostic and environmental purposes, for exam-
ple for virus detection or in disease diagnostics where spe-
cific vesicle types can serve as valuable markers. It is impor-
tant to stress that the nanochannels are well suited for
integration in fully automated lab-on-a-chip devices where
further analytical components, including modules for extra-
cellular vesicle purification,78 collection79 lysis80 or further
analysis80 can be integrated.
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